GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Price-to-Tangible-Book

Pulmonx (Pulmonx) Price-to-Tangible-Book : 3.15 (As of May. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Price-to-Tangible-Book?

As of today (2024-05-13), Pulmonx's share price is $8.77. Pulmonx's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $2.79. Hence, Pulmonx's Price to Tangible Book Ratio of today is 3.15.

The historical rank and industry rank for Pulmonx's Price-to-Tangible-Book or its related term are showing as below:

LUNG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.09   Med: 4.06   Max: 11.03
Current: 3.14

During the past 6 years, Pulmonx's highest Price to Tangible Book Ratio was 11.03. The lowest was 2.09. And the median was 4.06.

LUNG's Price-to-Tangible-Book is ranked worse than
53.15% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 2.75 vs LUNG: 3.14

A closely related ratio is called PB Ratio. As of today, Pulmonx's share price is $8.77. Pulmonx's Book Value per Sharefor the quarter that ended in Mar. 2024 was $2.85. Hence, Pulmonx's P/B Ratio of today is 3.08.


Pulmonx Price-to-Tangible-Book Historical Data

The historical data trend for Pulmonx's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Price-to-Tangible-Book Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - 11.03 6.21 2.09 4.24

Pulmonx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.98 3.79 3.21 4.24 3.33

Competitive Comparison of Pulmonx's Price-to-Tangible-Book

For the Medical Devices subindustry, Pulmonx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmonx's Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Pulmonx's Price-to-Tangible-Book falls into.



Pulmonx Price-to-Tangible-Book Calculation

Pulmonx's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=8.77/2.787
=3.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Pulmonx Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Pulmonx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51